MedElevator Войти в исследования
← Поиск публикаций

DOI 10.36141/svdld.v40i3.14418

Медицинская библиотека · Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2023

Risk factors for the development of interstitial lung disease following severe COVID-19 pneumonia and outcomes of systemic corticosteroid therapy: 3-month follow-up.

Günay Sibel, Parlak Izzet Selcuk, Hezer Habibe, Şeref Parlak Ebru Şengül, Umut Melike Sanem, Hancıoğlu Zeynep, Çelenk Ergüden Hülya, Kocaman Yasin, Dalkıran Aynil, Sertçelik Ümran, Şerifoğlu İrem, Akpınar Esmehan, Göktaş Muhammet Furkan, Fidan Meltem, Babahanoğlu Büşra, Cander Fatma Sinem, Çıvgın Esra, Er Mükremin, Kılıç Hatice, Argüder Emine, Tuğ Tuncer, Ünsal Ebru, Hasanoğlu Canan, Günay İrem, Babayiğit Muhammet, Ağca Büşra, Karalezli Ayşegül

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

We aimed to evaluate the pulmonary involvement status, its related factors, and pulmonary function test (PFT) results in the first month follow-up in patients who were discharged for severe Covid-19 pneumonia, and to assess the efficacy of corticosteroid treatment on these parameters in severe pulmonary involvement patients.

METHODS

We retrospectively analyzed all consecutive patients who applied to our COVID-19 follow-up clinic at the end of the first month of hospital discharge. Functional and radiological differences were compared after 3 months of corticosteroid treatment in severe pulmonary involvement group. Results We analyzed 391 patients with "pulmonary parenchymal involvement" (PPIG) and 162 patients with "normal lung radiology" (NLRG). 122 patients in the PPIG (corticosteroid-required interstitial lung disease group (CRILD)) had severe pulmonary involvement with frequent symptoms and required corticosteroid prescription. Pulmonary involvement was more common in males and elder patients (P<0.001, for both). Being smoker and elderly were associated with a higher risk-ratio in predicting to be in PPIG (OR:2.250 and OR:1.057, respectively). Smokers, male and elderly patients, and HFNO2 support during hospitalization were risk factors for being a patient with CRILD (OR:2.737, OR:4.937, OR:4.756, and OR:2.872, respectively). After a three-months of methylprednisolone medication, a good response was achieved on radiological findings and PFT results in CRILD.

CONCLUSIONS

In conclusion, after severe COVID-19 pneumonia, persistent clinical symptoms and pulmonary parenchymal involvement would be inevitable in elder and smoker patients. Moreover, corticosteroid treatment in patients with severe parenchymal involvement was found to be effective in the improvement of radiological and functional parameters.

Для цитирования: Günay Sibel, Parlak Izzet Selcuk, Hezer Habibe, Şeref Parlak Ebru Şengül, Umut Melike Sanem, Hancıoğlu Zeynep, Çelenk Ergüden Hülya, Kocaman Yasin, Dalkıran Aynil, Sertçelik Ümran, Şerifoğlu İrem, Akpınar Esmehan, Göktaş Muhammet Furkan, Fidan Meltem, Babahanoğlu Büşra, Cander Fatma Sinem, Çıvgın Esra, Er Mükremin, Kılıç Hatice, Argüder Emine, Tuğ Tuncer, Ünsal Ebru, Hasanoğlu Canan, Günay İrem, Babayiğit Muhammet, Ağca Büşra, Karalezli Ayşegül. Risk factors for the development of interstitial lung disease following severe COVID-19 pneumonia and outcomes of systemic corticosteroid therapy: 3-month follow-up.. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG. 2023. DOI: 10.36141/svdld.v40i3.14418.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.